Using Fascia Lata Membrane Versus Connective Tissue Graft in Immediate Implants
Vestibular Socket Therapy Using Fascia Lata Membrane Versus Connective Tissue Graft in Immediate Implants of Aesthetic Zone
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt
- Tanta University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Class II socket according to Elian et al, described as facial soft tissue is present but the buccal plate is partially missing following extraction of the tooth in the maxillary anterior region.
- Thin gingival phenotype.
- Bone quality ranges from D2-D3 as gained from preoperative cone-beam computed tomography.
- Presence of at least 3 mm of keratinized gingiva.
- Optimal compliance as evidenced by no missing treatment appointments and a positive attitude towards oral hygiene
Exclusion Criteria:
- Medically compromised patients and systemic conditions precluding implant and periodontal surgery.
- Smokers, diabetics, pregnant or lactating women.
- History of chemotherapy, radiotherapy in head and/or neck region.
- Bisphosphonate therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fascia lata membrane
|
immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
|
|
Active Comparator: Connective tissue graft both with xenogenic lamina membrane
|
immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in peri-implant mucosal level
Time Frame: at baseline, 6 months and 12 months
|
The changes in peri-implant mucosal level will be assessed by superimposition of scanning files of different intervals to monitor the changes in surface area calculated by software.
|
at baseline, 6 months and 12 months
|
|
Changes in gingival phenotype
Time Frame: at baseline, 6 months and 12 months
|
The changes in gingival phenotype could be assessed at 6 months and 12 months intervals by superimposition of DICOM files on CBCT software.
|
at baseline, 6 months and 12 months
|
|
Chaneg in height of labial (facial) plate of bone
Time Frame: at baseline, 6 months and 12 months
|
Cone beam computed tomography (CBCT)
|
at baseline, 6 months and 12 months
|
|
Chaneg in thickness of labial (facial) plate of bone
Time Frame: at baseline, 6 months and 12 months
|
Cone beam computed tomography (CBCT)
|
at baseline, 6 months and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- VST_21_22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.